An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients
Not Applicable
Completed
- Conditions
- Pneumonia, Pneumocystis CariniiHIV Infections
- Registration Number
- NCT00002030
- Lead Sponsor
- Fisons
- Brief Summary
To evaluate the safety, tolerability, and efficacy of long term, bi-weekly administration of aerosol pentamidine when used as a prophylactic agent in patients who have had at least two or more episodes of AIDS-associated Pneumocystis carinii pneumonia (PCP).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie aerosol pentamidine's efficacy in preventing Pneumocystis carinii pneumonia in HIV-positive individuals?
How does aerosol pentamidine compare to trimethoprim-sulfamethoxazole in long-term PCP prophylaxis for AIDS patients?
Are there specific biomarkers that predict response to aerosol pentamidine in patients with recurrent PCP episodes?
What are the long-term adverse events associated with bi-weekly aerosol pentamidine administration in immunocompromised HIV patients?
What alternative or combination therapies have been explored for Pneumocystis carinii pneumonia prophylaxis alongside pentamidine?
Trial Locations
- Locations (1)
Fisons Corp
🇺🇸Rochester, New York, United States
Fisons Corp🇺🇸Rochester, New York, United States